[go: up one dir, main page]

PE20200726A1 - Composicion de cannabis - Google Patents

Composicion de cannabis

Info

Publication number
PE20200726A1
PE20200726A1 PE2019000330A PE2019000330A PE20200726A1 PE 20200726 A1 PE20200726 A1 PE 20200726A1 PE 2019000330 A PE2019000330 A PE 2019000330A PE 2019000330 A PE2019000330 A PE 2019000330A PE 20200726 A1 PE20200726 A1 PE 20200726A1
Authority
PE
Peru
Prior art keywords
refers
weight
cannabis composition
extract
cannabis
Prior art date
Application number
PE2019000330A
Other languages
English (en)
Inventor
Harry Karelis
Mara Gordon
Stewart Smith
Stewart Washer
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61072172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20200726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of PE20200726A1 publication Critical patent/PE20200726A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Se refiere a una composicion farmaceutica que comprende un extracto de Cannabis y opcionalmente uno o mas portadores, diluyentes y excipientes, el extracto de Cannabis comprende 0% a 90% de ?9-Tetrahidrocannabinol (THC), 0% a 20% de Cannabidiol (CDB), 0% a 20% de Cannabinodiol (CBN), 0% a 20% de beta-mirceno en peso del extracto y una fraccion de terpeno que comprende limoneno al menos 5.4 % en peso de la fraccion del terpeno. Tambien se refiere a un metodo para tratar un trastorno del sueno.
PE2019000330A 2016-08-03 2017-08-03 Composicion de cannabis PE20200726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662370304P 2016-08-03 2016-08-03
PCT/AU2017/050814 WO2018023163A1 (en) 2016-08-03 2017-08-03 Cannabis composition

Publications (1)

Publication Number Publication Date
PE20200726A1 true PE20200726A1 (es) 2020-07-21

Family

ID=61072172

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000330A PE20200726A1 (es) 2016-08-03 2017-08-03 Composicion de cannabis

Country Status (15)

Country Link
US (2) US11779562B2 (es)
EP (1) EP3493798A4 (es)
JP (1) JP2019523283A (es)
KR (2) KR20190035791A (es)
CN (1) CN109843287A (es)
AU (4) AU2017307643B2 (es)
BR (1) BR112019001852A2 (es)
CA (1) CA3031810A1 (es)
CL (1) CL2019000270A1 (es)
CO (1) CO2019001044A2 (es)
IL (2) IL264461B2 (es)
MX (1) MX386620B (es)
PE (1) PE20200726A1 (es)
SG (1) SG11201900665VA (es)
WO (1) WO2018023163A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017307643B2 (en) 2016-08-03 2019-07-25 Zelira Therapeutics Operations Pty Ltd Cannabis Composition
KR102447510B1 (ko) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2577810A (en) * 2017-03-30 2020-04-08 Ojai Energetics Pbc Methods and compositions for enhancing health
CN110944632A (zh) 2017-06-19 2020-03-31 塞尔达治疗手术有限公司 睡眠障碍组合物及其治疗
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
WO2019173242A1 (en) * 2018-03-04 2019-09-12 Cmg Partners, Inc. Enhanced smokable cannabis-based therapeutic product for treatment of sleep disorders and chronic pain and method for making same
WO2019241804A1 (en) * 2018-06-15 2019-12-19 California Cannabinoids Compositions and methods for treatment of narcolepsy and related disorders
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020168073A1 (en) * 2019-02-13 2020-08-20 Caras Jim Composition comprising hydrolyzed collagen and cannabidiol and use thereof
NL2022616B1 (en) 2019-02-21 2020-09-18 Patrick Alexander Unger Cannabigerol and pharmaceutical compositions comprising cannabigerol for use in the treatment of insomnia
US11554098B2 (en) 2019-05-03 2023-01-17 HFL Partners, LLC Compositions comprising molecularly separated cannabinoids and terpene blends and methods of producing
EP4076485A4 (en) * 2019-12-19 2024-03-27 Steven Rothstein EXTRACTS ENRICHED WITH POLYPHENOLIC COMPOUNDS AND ASSOCIATED METHODS
US11000818B1 (en) * 2019-12-27 2021-05-11 Cresco Labs Llc Post processing method for cannabis oil
IT202000017137A1 (it) * 2020-07-15 2022-01-15 Linnea Sa Estratti di cannabis sativa e loro usi
US20230000935A1 (en) * 2021-07-03 2023-01-05 Joseph Anthony Bidwell Extract Infused Cannabis Flower, Natural preservation of Cannabis Flower and the method therefor
US20250144122A1 (en) * 2023-11-06 2025-05-08 Roberto Colon-Cruz Scent-Changing Ointment & Method of Making The Same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2400320B (en) 2001-05-04 2005-06-08 Gw Pharma Ltd Cannabinoid-rich extracts
JP4411117B2 (ja) * 2004-03-25 2010-02-10 エスエス製薬株式会社 睡眠改善医薬組成物
GB2418612A (en) 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
JP2007246428A (ja) * 2006-03-15 2007-09-27 Nature Technology Inc 植物精油成分を有効成分とする経皮吸収型睡眠覚醒用医薬組成物、その組成物を含有する経皮吸収型睡眠覚醒用医薬製剤、及びこれらの製造方法
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
KR20110120153A (ko) * 2010-04-28 2011-11-03 고려대학교 산학협력단 리모넨을 함유하는 아데노신 Ａ2ａ 수용체 작용제
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496688B (en) 2011-11-21 2016-06-29 Gw Pharma Ltd Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
SI2844243T1 (sl) 2012-05-03 2020-02-28 Echo Pharmaceuticals B.V. Metoda za pripravo izolata iz rastline konoplje, ki obsega delta-9-tetrahidrokanabinol
CA2895805A1 (en) * 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
US10792318B2 (en) 2013-03-14 2020-10-06 Sc Laboratories, Inc. Bioactive concentrates and uses thereof
US9095554B2 (en) * 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
US10265292B2 (en) 2013-09-18 2019-04-23 The Werc Shop, LLC Terpene-based compositions, processes methodologies
PT3062606T (pt) * 2013-10-29 2019-07-17 Biotech Inst Llc Reprodução, produção, transformação e uso de canábis especial
JP2016537412A (ja) 2013-10-31 2016-12-01 フル スペクトラム ラボラトリーズ，エルティーディー． テルペン及びカンナビノイドの製剤
CA3111682A1 (en) * 2014-06-26 2015-12-30 Island Breeze Systems Ca, Llc Mdi related products and methods of use
WO2015200864A1 (en) 2014-06-27 2015-12-30 Crowley Kenton L Buccal and sublingual cannabinoid formulations and method of making the same
WO2016030369A1 (en) * 2014-08-25 2016-03-03 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
NZ731248A (en) 2014-10-21 2024-04-26 United Cannabis Corp Cannabis extracts and methods of preparing and using same
JP2018505912A (ja) 2014-12-12 2018-03-01 オーハイ エナジェティクス ピービーシー マイクロカプセル化カンナビノイド組成物
EP3250200A4 (en) * 2015-01-31 2018-09-19 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
MX2017010872A (es) 2015-02-27 2018-05-07 Ebbu Llc Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CN109789124A (zh) 2016-08-03 2019-05-21 塞尔达治疗手术有限公司 大麻属组合物
KR102447510B1 (ko) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
AU2017307643B2 (en) 2016-08-03 2019-07-25 Zelira Therapeutics Operations Pty Ltd Cannabis Composition
CN110944632A (zh) 2017-06-19 2020-03-31 塞尔达治疗手术有限公司 睡眠障碍组合物及其治疗
AU2018333282A1 (en) 2017-09-15 2020-03-19 Zelira Therapeutics Operations Pty Ltd Composition and method for treating autism
AU2018100924A4 (en) 2018-07-03 2018-08-09 Zelira Therapeutics Operations Pty Ltd Composition and method for treating pain
JP2023529476A (ja) 2020-06-12 2023-07-10 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド 慢性疼痛を治療するための組成物及び方法
JP2023552004A (ja) 2020-11-06 2023-12-13 ゼリラ セラピューティクス オペレーションズ ピーティーワイ リミテッド カンナビノイドカプセル化技術

Also Published As

Publication number Publication date
CO2019001044A2 (es) 2019-04-30
CN109843287A (zh) 2019-06-04
SG11201900665VA (en) 2019-02-27
BR112019001852A2 (pt) 2019-05-07
US12239628B2 (en) 2025-03-04
MX386620B (es) 2025-03-19
IL296008B2 (en) 2024-09-01
IL296008A (en) 2022-10-01
EP3493798A4 (en) 2020-05-06
MX2019001285A (es) 2019-06-13
AU2018100923C4 (en) 2019-10-31
IL264461B1 (en) 2024-05-01
AU2021240297B2 (en) 2023-08-24
US20220347155A1 (en) 2022-11-03
JP2019523283A (ja) 2019-08-22
WO2018023163A1 (en) 2018-02-08
AU2018100923B4 (en) 2018-09-27
CA3031810A1 (en) 2018-02-08
AU2019253841A1 (en) 2019-11-14
IL264461A (en) 2019-02-28
IL264461B2 (en) 2024-09-01
KR20210013645A (ko) 2021-02-04
AU2017307643A1 (en) 2018-07-05
IL296008B1 (en) 2024-05-01
AU2017307643B2 (en) 2019-07-25
AU2019253841B2 (en) 2021-07-01
CL2019000270A1 (es) 2019-10-04
EP3493798A1 (en) 2019-06-12
KR20190035791A (ko) 2019-04-03
US20230414559A1 (en) 2023-12-28
US11779562B2 (en) 2023-10-10
AU2018100923A4 (en) 2018-08-09
AU2021240297A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
PE20200726A1 (es) Composicion de cannabis
PE20230607A1 (es) Composicion de cannabis
CL2019003635A1 (es) Composiciones y tratamientos para el trastorno del sueño.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
PE20200676A1 (es) Composicion de cannabis
MX2021002046A (es) Producto infundido con cannabis con experiencia de usuario de perfil de cannabinoides prolongado.
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
CO2017008437A2 (es) Métodos de purificación de cannabinoides, composiciones y kits de los mismos
MX2018011348A (es) Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades.
MX2017010872A (es) Composiciones que comprenden combinaciones de cannabinoides purificados, con al menos uno de flavonoides, terpenos o minerales.
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX2017004761A (es) Uso de cannabinoides en el tratamiento de enfermedades degenerativas del musculo esqueletico.
CL2018003489A1 (es) Composición y método para reducir neutropenia
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
PE20171138A1 (es) Modulacion inmunitaria
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
MX2017004998A (es) Composicion que contiene un extracto o fraccion de una planta del genero justicia.
BR112016017612A2 (pt) Uso de um extrato de uma planta do gênero mentha da família lamiaceae
MX2020004232A (es) Composiciones de cannabinoides y sus metodos de uso.
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
MX2018013538A (es) Productos de zumo y métodos para reducir el oscurecimiento enzimático.
CO2021001059A2 (es) Composición de cannabinoides y método para tratar el ptsd y/o la ansiedad
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite